4.6 Article

Investing in Justice: Ethics, Evidence, and the Eradication Investment Cases for Lymphatic Filariasis and Onchocerciasis

Journal

AMERICAN JOURNAL OF PUBLIC HEALTH
Volume 105, Issue 4, Pages 629-636

Publisher

AMER PUBLIC HEALTH ASSOC INC
DOI: 10.2105/AJPH.2014.302454

Keywords

-

Funding

  1. Hecht-Levi Fellowship in Bioethics, Johns Hopkins Berman Institute of Bioethics
  2. National Institute of Allergy and Infectious Diseases, National Institutes of Health [R56AI114458, 2T32AI729121]
  3. Bill and Melinda Gates Foundation [OPP1037660]
  4. Bill and Melinda Gates Foundation [OPP1037660] Funding Source: Bill and Melinda Gates Foundation

Ask authors/readers for more resources

It has been suggested that initiatives to eradicate specific communicable diseases need to be informed by eradication investment cases to assess the feasibility, costs, and consequences of eradication compared with elimination or control. A methodological challenge of eradication investment cases is how to account for the ethical importance of the benefits, burdens, and distributions thereof that are salient in people's experiences of the diseases and related interventions but are not assessed in traditional approaches to health and economic evaluation. We have offered a method of ethical analysis grounded in theories of social justice. We have described the method and its philosophical rationale and illustrated its use in application to eradication investment cases for lymphatic filariasis and onchocerciasis, 2 neglected tropical diseases that are candidates for eradication.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available